IMA402 (TCR Bispecific)

About Immatics

Immatics is dedicated to developing transformative T-cell receptor (TCR) therapies to address the significant unmet need in solid tumors. Its core strength lies in its proprietary discovery platforms that identify novel, cancer-specific targets presented by HLA molecules, enabling the development of highly specific TCR-based therapeutics. The company has established strategic partnerships with major players like Bristol Myers Squibb and has multiple clinical-stage assets, including TCR-T cell therapies and TCR Bispecifics, positioning it at the forefront of the next wave of immuno-oncology.

Therapeutic Areas

Other Advanced solid tumors Drugs